SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a massive $27 billion AI infrastructure deal with Meta, which significantly bolsters the company's long-term contracted backlog. While the community is debating the impact of a new $3.75 billion convertible debt offering intended to fund this rapid expansion, many remain bullish on the stock's long-term potential due to sustained backing from industry giants like NVIDIA and Microsoft.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is experiencing heightened volatility and trading volume as investors position themselves ahead of the upcoming fourth-quarter earnings release and monitor key regulatory milestones. The community is actively debating the company's long-term potential as a provider of nuclear energy for AI data centers versus concerns regarding its pre-revenue status, recent insider selling, and the broader macro-driven rotation out of high-beta speculative equities.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is drawing significant attention following its Nasdaq IPO and volatile market debut, with investors debating the growth potential of its drone autonomy software currently deployed in combat zones.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and heavy trading volume ahead of the upcoming Optical Fiber Communications Conference (OFC), as market participants speculate on potential major partnership announcements and purchase orders. Community sentiment remains polarized between long-term investors tracking institutional accumulation and technical alignment with hyperscale AI hardware, and skeptics voicing concerns over persistent pre-revenue status and reliance on strategic collaborations.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is experiencing heightened volatility and investor attention following positive Phase 3 clinical data for its Retevmo therapy and reports that the company has built significant inventory ahead of a potential April FDA decision on its oral obesity pill. Meanwhile, the broader community remains focused on the intense competitive landscape between LLY and Novo Nordisk, closely monitoring pricing strategies, new drug delivery formats, and ongoing regulatory scrutiny regarding the compounded weight-loss drug market.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to a significant insider purchase of 550,458 shares and a completed capital raise, which the community views as a major vote of confidence in the company's clinical trajectory. Sentiment is currently divided between long-term holders focusing on upcoming Phase 3 milestones and BLA filings, and skeptics who remain concerned about the impact of dilution on shareholder value.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing active community discussion as traders monitor potential buyout interest and growth prospects for its MS therapy, BRIUMVI, ahead of the company's upcoming earnings call. Investors are focused on the firm's revenue trajectory, recent long-term clinical data, and the potential impact of share repurchases on stock performance.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors monitor the appointment of a new CFO and anticipate the potential announcement of a major hyperscaler tenant. While some community members remain skeptical of management's communication and deal timelines, others are optimistic that the company's behind-the-meter energy model will drive significant long-term growth as infrastructure demand for AI continues to rise.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to a preliminary update from its Phase 3 FLAMINGO-01 trial, which revealed an exceptionally low recurrence rate of less than 1% per year in the open-label arm. Investors are heavily discussing the significance of these consistent long-term results, with the community actively speculating on upcoming abstract titles for the AACR annual meeting and potential strategic partnerships or buyouts.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to a significant settlement regarding patent litigation, a move that removes a long-standing legal overhang and shifts market focus toward the company's robust oncology pipeline and combination vaccine potential. Community discussion is heavily focused on the stock's high short interest and the potential for a major strategic partnership or buyout to accelerate future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Citi’s CFO in the earnings call this month had said that he expects to see headcount continue to trend downward.</li><li>Citigroup is reportedly expected to lay off more employees in March following a round of 1000 job cuts this month.&nbsp;</li><li>The new round of layoffs is expected to be announced after bonuses are paid, a report from Reuters News said.</li></ul>Citigroup will continue to cut more jobs in 2026, as part of its CEO’s reorganization efforts, a company spokesperson told Stocktwits on Thursday.&nbsp;“We will continue to reduce our headcount in 2026,” a company spokesperson said in an emailed response to Stocktwits’ query.&nbsp;“These changes reflect adjustments we’re making to ensure our staffing levels, locations and expertise align with current business needs; efficiencies we have gained through technology; and progress against our Transformation work, which is nearing target state,” the spokesperson added.&nbsp;Shares in the company were down 1.7% at the time of writing.&nbsp;<h2 class="st-heading-2">Cuts In March</h2>Citigroup is reportedly expected to lay off more employees in March following a round of 1,000 job cuts this month.&nbsp;The new round of layoffs is expected to be announced after bonuses are paid, a report from Reuters News said, citing sources familiar with the matter.&nbsp;The March layoffs are likely to affect managing directors and senior employees across business lines and some senior managers have already been reassigned to different divisions to secure roles before headcount is reduced, the report added.&nbsp;<h2 class="st-heading-2">CEO’s Reorganization Efforts</h2>Citi’s CEO Jane Fraser has led the corporate reorganization efforts at the U.S. firm since taking up the role, in a bid to trim down management layers and fasten decision making.Citi’s Chief Financial Officer Mark Mason during its fourth quarter earnings call said that Citi's workforce shrank by 20,000 since 2022 and is now at 226,000 employees by the end of 2025.“We'll see that cost and headcount come down as we continue to improve productivity and implement tools like AI, we'd see an impact, or expect to see an impact on headcount. So, notwithstanding, insourcing and driving broader efficiency, I would expect to see headcount continue to trend downward,” he had said.&nbsp;<h2 class="st-heading-2">Recent Earnings</h2>Citi reported higher fourth quarter (Q4) profit buoyed by rebound in dealmaking activities, that beat analyst estimates. On an adjusted basis, Citi reported a ​profit of $1.81 per share during the quarter, compared with analysts' average estimate of $1.67, according to data from fiscal.ai.&nbsp;Citi’s investment banking fees in Q4 rose 35% to $1.29 billion, up from $951 million from a year-ago quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around Citi trended in ‘bearish’ territory amid ‘low’ message volume.&nbsp;Shares in the bank have risen 39% over the past 12 months.&nbsp; &nbsp;

A Citibank logo is displayed outside their bank on February 28, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Citi Will Cut More Jobs In 2026 As Part Of CEO’s Reorganization Efforts

A Citigroup spokesperson told Stocktwits that layoffs reflect adjustments Citi is making to ensure its staffing levels, locations and expertise align with current business needs. 

Equity

A Citigroup spokesperson told Stocktwits that layoffs reflect adjustments Citi is making to ensure its staffing levels, locations and expertise align with current business needs. 


<ul class="summary-bullets"><li>“We will continue to reduce our headcount in 2026”, the company said, as per the report.&nbsp;</li><li>CEO Jane Fraser has taken the corporate reorganization efforts at the U.S. firm since taking up the role</li><li>Citigroup is planning to report results on Wednesday and inform its staff of their bonuses for 2025. &nbsp;</li></ul>U.S. banking giant Citigroup is reportedly cutting 1000 jobs this week as part of its CEO Jane Fraser's cost-cutting efforts.The job cuts are part of the bank's plan announced two years ago to reduce staff by 20,000 before the end of 2026, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-12/citi-to-cut-about-1-000-jobs-this-week-as-fraser-trims-costs">report</a> from Bloomberg News that cited people familiar with the matter.&nbsp;Fraser has taken the corporate reorganization efforts at the U.S. firm since taking up the role, in a bid to trim down management layers and fasten decision making.&nbsp;“We will continue to reduce our headcount in 2026”, the company said, as per the report. It further added that these changes reflect adjustments the company is making to ensure staffing levels and expertise align with current business needs.&nbsp;<h2 class="st-heading-2">FY25 Results On The Horizon</h2>Citigroup is planning to report results on Wednesday and inform its staff of their bonuses for 2025.&nbsp;The company is expected to post a revenue of $20.5 billion for the fourth quarter (Q4) as per the data from Fiscal.ai. It is also expected to post a profit of $1.73 per share.&nbsp;<h2 class="st-heading-2">Improving Control Issues</h2>Citigroup has been improving its oversight and control deficiencies in its business. Last month, the Federal Reserve told the firm that it has closed formal notices requiring the bank to fix trading risk management weaknesses, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/us-fed-terminates-citi-notices-that-demanded-bank-improve-risk-controls-sources-2025-12-17/">report</a> from Reuters News.The Fed in 2023 had issued notices to Citi to address three so-called Matters Requiring Immediate Attention, or MRIAs, identifying problems relating to how the bank calculates and manages the risks of its trading partners and sets aside capital to cushion potential losses on those trades, the report added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around <a href="https://stocktwits.com/symbol/C">C</a> trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;Shares in Citigroup have risen nearly 66% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Chief executive officer of Citigroup Jane Fraser visits FOX Business Network's "Mornings With Maria" at Fox Business Network Studios on May 29, 2025 in New York City. (Photo by John Lamparski/Getty Images)

US Banking Giant Citigroup To Cut 1,000 Jobs This Week: Report

The job cuts are part of the bank's plan announced two years ago to reduce staff by 20,000 before the end of 2026, Bloomberg News report said. 

<ul class="summary-bullets"><li>Piper Sandler downgraded ALEX stock to ‘Neutral’ from ‘Overweight’ and kept the price target unchanged at $21.</li><li>Alexander &amp; Baldwin announced on Monday that it would go private in a deal worth $2.3 billion.&nbsp;</li><li>The company will be acquired by a MW Group joint venture for $21.20 per share by the first quarter of 2026, the company said in a statement.&nbsp; &nbsp;</li></ul>Shares of Alexander &amp; Baldwin (ALEX) rallied over 38% on Tuesday morning after the announcement of the $2.3 billion take-private deal.The company’s outstanding shares will be acquired at $21.20 per share by a joint venture formed among MW Group, Blackstone Real Estate, and DivcoWest, expected to close by the first quarter of 2026. The all-cash deal represents a 40% premium to the company’s closing price as of Dec. 8, 2025.&nbsp;In addition, Alexander &amp; Baldwin announced a fourth-quarter (Q4) 2025 dividend of $0.35 per share, payable on January 8, 2026.&nbsp;<h2 class="st-heading-2">Street Action</h2>Meanwhile, Piper Sandler downgraded ALEX to ‘Neutral’ from ‘Overweight’ before, while keeping the price target intact at $21, as cited on TheFly. Piper said that it has revised its rating following the announcement and does not expect a competing bid to emerge.“Today, we are taking an important step toward our long-term vision for A&amp;B as stewards of Hawai'i's premier commercial real estate. As a private company supported by the deep real estate expertise and experience of our new ownership group, A&amp;B will have greater capacity to serve its tenants and communities,” President and CEO Lance Parker said.&nbsp;Alexander &amp; Baldwin is the only publicly traded real estate investment trust focused solely on Hawaiian commercial real estate. The company owns about four million square feet of commercial space in Hawai'i.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALEX jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1276/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_8_30_30_PM_png_5f7959ea10.webp" alt="On Stocktwits, retail sentiment around ALEX jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels." width="1276" height="154"></figure>Shares of ALEX have climbed over 18% in the past year and returned almost 30% in the last five years.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com&nbsp;

Generic Image of Office Space (Photo by Fairfax Media via Getty Images via Getty Images)

Alexander & Baldwin Shares Shoot Through The Roof After $2.3B Take Private Deal – This Firm Has Downgraded The Stock

Shares of ALEX surged over 38% in pre-market trading while Piper Sandler downgraded the stock. 

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced on Thursday that the U.S. Food and Drug Administration has approved a generic version of the Liraglutide injection known as Saxenda.Liraglutide Injection is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated to reduce excess body weight and maintain weight reduction long-term in adults as well as pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. The drug is to be used in combination with a reduced-calorie diet and increased physical activity.“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tevapharm.com/news-and-media/latest-news/teva-announces-fda-approval-and-launch-of-generic-saxenda-liraglutide-injection--first-generic-glp-1-/">said</a> Ernie Richardsen, Head of U.S. Commercial Generics at Teva. He added that it marks an important addition to the company’s generics portfolio.Saxenda, Novo Nordisk’s older obesity drug, had annual sales of $165 million as of June 2025, the company said. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TEVA">TEVA stock</a> trended within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_9_52_29_AM_png_ba7ec14e95.webp" alt="TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise that the stock is not trading higher despite the approval.<stembedurl>https://stocktwits.com/RemitTekram/message/626845403</stembedurl>Another user sounded skeptical, saying that the stock would probably end the day in the red despite “explosive news.”<stembedurl>https://stocktwits.com/NoTradeAnymore/message/626842741</stembedurl>In the second quarter, Teva recorded revenue of $4.2 billion and adjusted and diluted earnings per share of $0.66. Generics product revenues in the U.S., however, fell 6% to $961 million, due to lower revenues from Lenalidomide capsules, the generic version of Revlimid, and Liraglutide injection 1.8mg, an authorized generic of Victoza, primarily driven by increased competition.TEVA stock is down 19% this year and approximately 3% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-receives-revised-proposal-to-acquire-company/chs6JRRRdmm">LakeShore Biopharma Receives Revised Proposal To Acquire Company</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A very overweight woman with swollen feet stands on a scale that reads 145.1 kilograms. Overweight and obesity are increasing at a rapid pace worldwide. Photo: Pia Bayer/dpa (Photo by Pia Bayer/picture alliance via Getty Images)

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

The company’s U.S. affiliate announced that the U.S. Food and Drug Administration has approved a generic version of Liraglutide injection, known as Saxenda.

IYLD
iShares Morningstar Multi-Asset Income ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IYLD News

IYLDiShares Morningstar Multi-Asset Income ETF